000290854 001__ 290854
000290854 005__ 20250814134742.0
000290854 0247_ $$2doi$$a10.1016/j.vaccine.2024.06.001
000290854 0247_ $$2pmid$$apmid:38839520
000290854 0247_ $$2ISSN$$a0264-410X
000290854 0247_ $$2ISSN$$a1358-8745
000290854 0247_ $$2ISSN$$a1873-2518
000290854 037__ $$aDKFZ-2024-01211
000290854 041__ $$aEnglish
000290854 082__ $$a610
000290854 1001_ $$aCacciotto, Carla$$b0
000290854 245__ $$aOvine papillomavirus type 3 virus-like particle-based tools for diagnosis and detection of infection.
000290854 260__ $$aAmsterdam$$bElsevier$$c2024
000290854 3367_ $$2DRIVER$$aarticle
000290854 3367_ $$2DataCite$$aOutput Types/Journal article
000290854 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1725433670_15636
000290854 3367_ $$2BibTeX$$aARTICLE
000290854 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290854 3367_ $$00$$2EndNote$$aJournal Article
000290854 500__ $$a2024 Sep 17;42(22):126033
000290854 520__ $$aThe design of prophylactic and diagnostic tools specific to animal papillomaviruses is hampered by the difficulties of viral in vitro manipulation and by the scarce availability of dedicated biotechnological tools. This paper reports the production of Ovine Papillomavirus 3 (OaPV3)-based virus-like particles (OaPV3-VLPs) in the baculovirus system and their use to investigate host humoral immune response through the establishment of an indirect ELISA test., Polyclonal sera and monoclonal antibodies were generated against OaPV3-VLPs, and their isotype and reactivity were determined. Additionally, antibodies allowed OaPV3 detection in ovine squamous cell carcinoma (SCC) samples by immunohistochemistry. Results encourage the standardization of OaPV3-specific prophylactic and serological diagnostic tools, and open new perspectives for the study of host-viral interaction and SCC development.
000290854 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000290854 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290854 650_7 $$2Other$$aAnimal papillomavirus
000290854 650_7 $$2Other$$aOncovirus
000290854 650_7 $$2Other$$aSerogical diagnosis
000290854 650_7 $$2Other$$aSkin cancer
000290854 650_7 $$2Other$$aVaccines
000290854 7001_ $$aDore, Gian Mario$$b1
000290854 7001_ $$aCubeddu, Tiziana$$b2
000290854 7001_ $$aBurrai, Giovanni Pietro$$b3
000290854 7001_ $$aAnfossi, Antonio Giovanni$$b4
000290854 7001_ $$aAntuofermo, Elisabetta$$b5
000290854 7001_ $$aVaroni, Maria Vittoria$$b6
000290854 7001_ $$aDemontis, Maria Piera$$b7
000290854 7001_ $$aZobba, Rosanna$$b8
000290854 7001_ $$aPittau, Marco$$b9
000290854 7001_ $$0P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aMüller, Martin$$b10$$udkfz
000290854 7001_ $$aAlberti, Alberto$$b11
000290854 773__ $$0PERI:(DE-600)1468474-3$$a10.1016/j.vaccine.2024.06.001$$gp. S0264410X24006601$$n22$$p126033$$tVaccine$$v42$$x0264-410X$$y2024
000290854 8564_ $$uhttps://inrepo02.dkfz.de/record/290854/files/1-s2.0-S0264410X24006601-main.pdf
000290854 8564_ $$uhttps://inrepo02.dkfz.de/record/290854/files/1-s2.0-S0264410X24006601-main.pdf?subformat=pdfa$$xpdfa
000290854 909CO $$ooai:inrepo02.dkfz.de:290854$$pVDB
000290854 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000290854 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000290854 9141_ $$y2024
000290854 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000290854 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bVACCINE : 2022$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000290854 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bVACCINE : 2022$$d2023-10-21
000290854 9201_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000290854 980__ $$ajournal
000290854 980__ $$aVDB
000290854 980__ $$aI:(DE-He78)D335-20160331
000290854 980__ $$aUNRESTRICTED